SHARPE
Reported results
- Total Consolidated Net Sales increased 27.0% to $151.1 million.
- GAAP Gross Profit increased 20.9% to $85.2 million.
- GAAP Net Income decreased 81.4% to $3.9 million.
- Non-GAAP Adjusted EBITDA decreased 41.3% to $18.4 million.
- GAAP Diluted EPS was $0.19 compared to $1.13 in the prior-year period.
- Non-GAAP Adjusted Diluted EPS was $0.41 compared to $1.05 in the prior-year period.
Guidance
- Full year 2026 Modern Oral Gross Sales of $330-$350 million
- Full year 2026 Modern Oral Net Sales of $260-$270 million
- Full Year 2026 Adjusted EBITDA of $70-$80 million
Price and volatility reaction
The stock moved -4.0% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 65.88 | 2026-11-06 |
| Close after release | 63.26 | 2026-11-09 |
| Realised move | -4.0% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.